Elizabeth Joseloff

Pulmonary Hypertension Association — United States

Medicine · Health Sciences

17h-index1.7kcitations36works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(17), Neonatal Respiratory Health Research(8), Pulmonary Hypertension Research and Treatments(4), Asthma and respiratory diseases(3), Advanced Proteomics Techniques and Applications(3)

Publications36 total

American Lung Association Pulmonary Hypertension Roundtable: Executive Summary
Pulmonary Circulation·2025Open Access
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Journal of the American Heart Association·2025· 4 citedOpen Access
Are We Moving the Needle? Assessing the Effectiveness of a Virtual Course Series for Pulmonary Hypertension
American Journal of Respiratory and Critical Care Medicine·2025
Association of Male Sex With Worse Right Ventricular Function and Survival in Pulmonary Hypertension in the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Cohort
CHEST Pulmonary·2024· 8 citedOpen Access
Targeted Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance Regulator in the Apical Plasma Membrane
Figshare·2020Open Access
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
UNC Libraries·2020Open Access
PATIENT VOLUMES AND PHYSICIAN/NON-PHYSICIAN COORDINATOR STAFFING IN PHA-ACCREDITED CENTERS OF COMPREHENSIVE CARE AND REGIONAL CLINICAL PROGRAMS
CHEST Journal·2020Open Access
Author rebuttal to response regarding “Letter to the Editor regarding ‘Could pulmonary arterial hypertension patients be at lower risk from severe COVID‐19?’”
Pulmonary Circulation·2020· 6 citedOpen Access
Biomarkers for cystic fibrosis drug development
UNC Libraries·2020· 1 citedOpen Access
Could pulmonary arterial hypertension patients be at a lower risk from severe COVID‐19?
Pulmonary Circulation·2020· 64 citedOpen Access
Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity
Journal of Cystic Fibrosis·2019· 13 citedOpen Access
Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis
Journal of Cystic Fibrosis·2018· 14 citedOpen Access
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
Journal of Cystic Fibrosis·2018· 23 citedOpen Access
CFTR modulator theratyping: Current status, gaps and future directions
Journal of Cystic Fibrosis·2018· 283 citedOpen Access
WS16.6 Human epididymis protein 4 (HE4) plasma levels inversely correlate with improved FEV1 in cystic fibrosis patients under ivacaftor therapy as a new sensitive treatment efficacy biomarker
Journal of Cystic Fibrosis·2018Open Access
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations
Journal of Cystic Fibrosis·2018· 38 citedOpen Access
Take it to the Bank
Journal of Cystic Fibrosis·2017· 1 cited
Pediatric Pulmonology
Pediatric Pulmonology·2017· 20 citedOpen Access
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
Clinical and Translational Gastroenterology·2017· 147 citedOpen Access
Biomarkers for cystic fibrosis drug development
Journal of Cystic Fibrosis·2016· 65 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sonya L. Heltshe(10), Drucy Borowitz(6), Scott D. Sagel(6), Steven M. Rowe(5), Evelyn M. Horn(5), Erika B. Rosenzweig(5), Margarida D. Amaral(4), Diana Wetmore(4), Joseph M. Pilewski(4), Marianne S. Muhlebach(4), Scott H. Donaldson(3), Daniel Gelfond(3), Bonnie W. Ramsey(3), Michael Boyle(3), Stuart H. Yuspa(3), Assem Ziady(3), Frank J. Accurso(3), Murali M. Chakinala(3), Ronald J. Oudiz(3), Robert P. Frantz(3)